MedPath

Takeda Pharmaceutical Company Ltd

🇯🇵Japan
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/
Clinical Trials
Related News

Use of Tachosil® for Lymph Sealing During Surgery

Completed
Conditions
Lymph Node Resection
Interventions
Other: TachoSil®
First Posted Date
2013-08-12
Last Posted Date
2016-12-19
Lead Sponsor
Takeda
Target Recruit Count
233
Registration Number
NCT01920958

Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation

Phase 2
Completed
Conditions
Hypothyroidism
Interventions
First Posted Date
2013-08-05
Last Posted Date
2015-07-20
Lead Sponsor
Takeda
Target Recruit Count
101
Registration Number
NCT01916304

Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Phase 4
Completed
Conditions
Lymphoma
Interventions
First Posted Date
2013-07-29
Last Posted Date
2024-12-27
Lead Sponsor
Takeda
Target Recruit Count
50
Registration Number
NCT01909934
Locations
🇵🇱

Malopolskie Centrum Medyczne s.c., Krakow, Poland

🇵🇱

Uniwersyteckie Centrum Kliniczne, Gdansk, Poland

🇧🇪

Cliniques Universitaires Saint-Luc, Bruxelles, Belgium

and more 37 locations

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

First Posted Date
2013-07-16
Last Posted Date
2015-02-19
Lead Sponsor
Takeda
Target Recruit Count
76
Registration Number
NCT01900522

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

Phase 1
Completed
Conditions
Psychotic-like Symptoms
Ketamine-Induced Brain Activity Changes
Interventions
Drug: TAK-063 Placebo
First Posted Date
2013-07-04
Last Posted Date
2017-01-12
Lead Sponsor
Takeda
Target Recruit Count
27
Registration Number
NCT01892189
Locations
🇺🇸

The Brain Institute, University of Utah, Salt Lake City, Utah, United States

Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes

First Posted Date
2013-07-01
Last Posted Date
2016-11-28
Lead Sponsor
Takeda
Target Recruit Count
647
Registration Number
NCT01890122

Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants

Phase 1
Completed
Conditions
Schizophrenia
Interventions
Drug: TAK-063 Placebo
First Posted Date
2013-06-18
Last Posted Date
2016-10-28
Lead Sponsor
Takeda
Target Recruit Count
77
Registration Number
NCT01879722

Observational Study in Preterm Neonates Who Are Sufficiently Stable on Non-Invasive Ventilatory Support

Completed
Conditions
Infant Respiratory Distress Syndrome
Non-invasive Ventilatory Support
Interventions
Other: Preterm Neonates
First Posted Date
2013-05-24
Last Posted Date
2014-08-22
Lead Sponsor
Takeda
Target Recruit Count
40
Registration Number
NCT01861795

Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of Chronic Venous Insufficiency

Phase 4
Completed
Conditions
Chronic Venous Insufficiency
Interventions
Drug: Coumarin/troxerutin
Drug: Placebo
First Posted Date
2013-05-07
Last Posted Date
2016-11-11
Lead Sponsor
Takeda
Target Recruit Count
829
Registration Number
NCT01848210

Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes

First Posted Date
2013-04-17
Last Posted Date
2015-09-28
Lead Sponsor
Takeda
Target Recruit Count
96
Registration Number
NCT01834274
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy